MetabolixAI

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Healthcare professionals, marketers and institutions spend nearly 40 per cent of their time creating and publishing content, which diverts resources from patient care, research and innovation.

Bringing Meta AI to Europe involved "almost a year of intensive engagement with various European regulators," the company says.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Medical errors are the third leading cause of death in the U.S., contributing to over 250,000 preventable deaths each year. NeuralCure AI is tackling this crisis head-on by eliminating diagnostic blind spots and accelerating treatment precision with its cutting-edge AI-driven decision support system.

Meta plans to add an artificial intelligence app to its stable of stand-alone offerings including Instagram, Facebook and WhatsApp.

Google has developed an AI tool to act as a virtual collaborator for biomedical scientists, the U.S. blue chip said on Wednesday.